ID   TREX1_MOUSE             Reviewed;         314 AA.
AC   Q91XB0; Q3TAD7; Q9D6W2; Q9R1B0;
DT   24-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   24-MAY-2004, sequence version 2.
DT   22-JUL-2015, entry version 113.
DE   RecName: Full=Three-prime repair exonuclease 1;
DE            EC=3.1.11.2;
DE   AltName: Full=3'-5' exonuclease TREX1;
DE   AltName: Full=DNase III;
GN   Name=Trex1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=10391904; DOI=10.1074/jbc.274.28.19655;
RA   Mazur D.J., Perrino F.W.;
RT   "Identification and expression of the TREX1 and TREX2 cDNA sequences
RT   encoding mammalian 3'-->5' exonucleases.";
RL   J. Biol. Chem. 274:19655-19660(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and NOD; TISSUE=Spleen, and Tongue;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF N-TERMINUS, FUNCTION, AND HOMODIMERIZATION.
RX   PubMed=11279105; DOI=10.1074/jbc.M100623200;
RA   Mazur D.J., Perrino F.W.;
RT   "Excision of 3' termini by the Trex1 and TREX2 3'-->5' exonucleases.
RT   Characterization of the recombinant proteins.";
RL   J. Biol. Chem. 276:17022-17029(2001).
RN   [5]
RP   FUNCTION IN INFLAMMATION, SUBCELLULAR LOCATION, AND DISRUPTION
RP   PHENOTYPE.
RX   PubMed=15254239; DOI=10.1128/MCB.24.15.6719-6727.2004;
RA   Morita M., Stamp G., Robins P., Dulic A., Rosewell I., Hrivnak G.,
RA   Daly G., Lindahl T., Barnes D.E.;
RT   "Gene-targeted mice lacking the Trex1 (DNase III) 3'-->5' DNA
RT   exonuclease develop inflammatory myocarditis.";
RL   Mol. Cell. Biol. 24:6719-6727(2004).
RN   [6]
RP   FUNCTION IN CELL CYCLE REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18045533; DOI=10.1016/j.cell.2007.10.017;
RA   Yang Y.G., Lindahl T., Barnes D.E.;
RT   "Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint
RT   activation and autoimmune disease.";
RL   Cell 131:873-886(2007).
RN   [7]
RP   FUNCTION AS REGULATOR OF IFN RESPONSE, SUBCELLULAR LOCATION, INDUCTION
RP   BY CYTOSOLIC DNA, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF ARG-114;
RP   HIS-195; ASP-200 AND VAL-201.
RX   PubMed=18724932; DOI=10.1016/j.cell.2008.06.032;
RA   Stetson D.B., Ko J.S., Heidmann T., Medzhitov R.;
RT   "Trex1 prevents cell-intrinsic initiation of autoimmunity.";
RL   Cell 134:587-598(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [9]
RP   FUNCTION IN OXIDIZED DNA DEGRADATION.
RX   PubMed=23993650; DOI=10.1016/j.immuni.2013.08.004;
RA   Gehrke N., Mertens C., Zillinger T., Wenzel J., Bald T., Zahn S.,
RA   Tueting T., Hartmann G., Barchet W.;
RT   "Oxidative damage of DNA confers resistance to cytosolic nuclease
RT   TREX1 degradation and potentiates STING-dependent immune sensing.";
RL   Immunity 39:482-495(2013).
RN   [10]
RP   FUNCTION IN INNATE IMMUNE SYSTEM REGULATION, TISSUE SPECIFICITY,
RP   DISRUPTION PHENOTYPE, AND INDUCTION BY INFLAMMATORY STIMULI.
RX   PubMed=24218451; DOI=10.4049/jimmunol.1301603;
RA   Pereira-Lopes S., Celhar T., Sans-Fons G., Serra M., Fairhurst A.M.,
RA   Lloberas J., Celada A.;
RT   "The exonuclease trex1 restrains macrophage proinflammatory
RT   activation.";
RL   J. Immunol. 191:6128-6135(2013).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 1-242 IN COMPLEXES WITH DNA;
RP   AMP; CALCIUM AND MANGANESE IONS, FUNCTION, CATALYTIC ACTIVITY,
RP   COFACTOR, SUBUNIT, AND MUTAGENESIS OF ARG-114 AND VAL-201.
RX   PubMed=17293595; DOI=10.1074/jbc.M700039200;
RA   de Silva U., Choudhury S., Bailey S.L., Harvey S., Perrino F.W.,
RA   Hollis T.;
RT   "The crystal structure of TREX1 explains the 3' nucleotide specificity
RT   and reveals a polyproline II helix for protein partnering.";
RL   J. Biol. Chem. 282:10537-10543(2007).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 9-245 AND MUTANT ALA-195 IN
RP   COMPLEXES WITH DNA AND MAGNESIUM IONS, FUNCTION, CATALYTIC ACTIVITY,
RP   ACTIVE SITE, COFACTOR, DNA-BINDING, SUBUNIT, INTERACTION WITH TCERG1,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF HIS-195.
RX   PubMed=17355961; DOI=10.1074/jbc.M700236200;
RA   Brucet M., Querol-Audi J., Serra M., Ramirez-Espain X., Bertlik K.,
RA   Ruiz L., Lloberas J., Macias M.J., Fita I., Celada A.;
RT   "Structure of the dimeric exonuclease TREX1 in complex with DNA
RT   displays a proline-rich binding site for WW Domains.";
RL   J. Biol. Chem. 282:14547-14557(2007).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 9-245 IN COMPLEXES WITH TMP;
RP   LITHIUM; SODIUM AND ZINC IONS, FUNCTION, CATALYTIC ACTIVITY,
RP   DNA-BINDING, COFACTOR, ENZYME REGULATION, AND MUTAGENESIS OF HIS-124
RP   AND HIS-195.
RX   PubMed=18780819; DOI=10.1110/ps.036426.108;
RA   Brucet M., Querol-Audi J., Bertlik K., Lloberas J., Fita I.,
RA   Celada A.;
RT   "Structural and biochemical studies of TREX1 inhibition by metals.
RT   Identification of a new active histidine conserved in DEDDh
RT   exonucleases.";
RL   Protein Sci. 17:2059-2069(2008).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 1-142 AND MUTANTS ASN-18;
RP   HIS-200; ASN-200 AND ASP-201 IN COMPLEXES WITH DNA; CALCIUM AND
RP   MAGNESIUM IONS, COFACTOR, AND SUBUNIT.
RX   PubMed=22071149; DOI=10.1016/j.dnarep.2011.10.007;
RA   Bailey S.L., Harvey S., Perrino F.W., Hollis T.;
RT   "Defects in DNA degradation revealed in crystal structures of TREX1
RT   exonuclease mutations linked to autoimmune disease.";
RL   DNA Repair 11:65-73(2012).
CC   -!- FUNCTION: Major cellular 3'-to-5' DNA exonuclease which digests
CC       single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) with
CC       mismatched 3' termini. Prevents cell-intrinsic initiation of
CC       autoimmunity. Acts by metabolizing DNA fragments from endogenous
CC       retroelements, including L1, LTR and SINE elements. Unless
CC       degraded, these DNA fragments accumulate in the cytosol and
CC       activate the IFN-stimulatory DNA (ISD) response and innate immune
CC       signaling. Prevents chronic ATM-dependent checkpoint activation,
CC       by processing ssDNA polynucleotide species arising from the
CC       processing of aberrant DNA replication intermediates.
CC       Inefficiently degrades oxidized DNA, such as that generated upon
CC       antimicrobial reactive oxygen production or upon absorption of UV
CC       light. During GZMA-mediated cell death, contributes to DNA damage
CC       in concert with NME1. NME1 nicks one strand of DNA and TREX1
CC       removes bases from the free 3' end to enhance DNA damage and
CC       prevent DNA end reannealing and rapid repair.
CC       {ECO:0000269|PubMed:10391904, ECO:0000269|PubMed:11279105,
CC       ECO:0000269|PubMed:15254239, ECO:0000269|PubMed:17293595,
CC       ECO:0000269|PubMed:17355961, ECO:0000269|PubMed:18045533,
CC       ECO:0000269|PubMed:18724932, ECO:0000269|PubMed:18780819,
CC       ECO:0000269|PubMed:23993650, ECO:0000269|PubMed:24218451}.
CC   -!- CATALYTIC ACTIVITY: Exonucleolytic cleavage in the 3'- to 5'-
CC       direction to yield nucleoside 5'-phosphates.
CC       {ECO:0000269|PubMed:17293595, ECO:0000269|PubMed:17355961,
CC       ECO:0000269|PubMed:18780819}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:17293595,
CC         ECO:0000269|PubMed:17355961, ECO:0000269|PubMed:18780819,
CC         ECO:0000269|PubMed:22071149};
CC       Note=Binds 2 Mg(2+) per subunit. The second magnesium ion
CC       interacts with only one residue. Substitution with Mn(2+) results
CC       in partial activity. {ECO:0000269|PubMed:17293595,
CC       ECO:0000269|PubMed:17355961, ECO:0000269|PubMed:18780819,
CC       ECO:0000269|PubMed:22071149};
CC   -!- ENZYME REGULATION: Calcium, lithium and sodium inhibit the
CC       exonuclease activity but not the DNA binding.
CC       {ECO:0000269|PubMed:18780819}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 7.5-8.0.;
CC   -!- SUBUNIT: Homodimer. Interacts (via proline-rich region) with
CC       TCERG1/CA150 (via the second WW domain). Component of the SET
CC       complex, composed of at least ANP32A, APEX1, HMGB2, NME1, SET and
CC       TREX1. Within this complex, directly interacts with SET; this
CC       interaction does not result in TREX1 inhibition. Also interacts
CC       with NME1, but only following translocation to the nucleus.
CC       Directly interacts with UBQLN1 (via ubiquitin-like domain); the
CC       interaction may control TREX1 subcellular location.
CC       {ECO:0000269|PubMed:17293595, ECO:0000269|PubMed:17355961,
CC       ECO:0000269|PubMed:22071149}.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm, cytosol. Endoplasmic
CC       reticulum membrane; Peripheral membrane protein. Note=Retained in
CC       the cytoplasm through the C-terminal region. In response to DNA
CC       damage, translocates to the nucleus where it is specifically
CC       recruited to replication foci. Translocation to the nucleus also
CC       occurs during GZMA-mediated cell death.
CC   -!- TISSUE SPECIFICITY: Widely expressed with high expression levels
CC       detected in spleen, thymus and uterus.
CC       {ECO:0000269|PubMed:24218451}.
CC   -!- INDUCTION: Induced by cytosolic DNA. Induced by inflammatory
CC       stimuli in a cell-specific fashion. Up-regulated by IFN-alpha and
CC       IFN-gamma in B-cells and by LPS and viral and bacterial DNA (via
CC       Toll-like receptor signaling) in dendritic cells and macrophages.
CC       {ECO:0000269|PubMed:18724932, ECO:0000269|PubMed:24218451}.
CC   -!- PTM: Ubiquitinated, but not targeted to proteasomal degradation.
CC       Ubiquitination may be important for interaction with UBQLN1 (By
CC       similarity). {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Mutant animals exhibit a dramatically
CC       reduced survival after weaning, with 50% of survival at 9 weeks
CC       (PubMed:18724932) or 17 weeks (PubMed:15254239). In 6-8 week old
CC       animals, multiple organs show extensive inflammation. The most
CC       severe diffuse lymphocytic infiltration occurs in the heart,
CC       followed by the lung, the liver, the smooth muscle of the uterus
CC       and the salivary gland with periductal infiltration. Other tissues
CC       exhibit only minimal to mild lymphocytic infiltration
CC       (PubMed:24218451). The heart phenotype includes inflammatory
CC       myocarditis leading to progressive, often dilated, cardiomyopathy
CC       and circulatory failure. Enlargement of the spleen and lymph nodes
CC       is observed in less than 10% of old mice (over 1 year of age)
CC       (PubMed:15254239). Mutant animals have a reduced 3'-exonuclease
CC       activity. They accumumulate ssDNA from endogenous retroelements
CC       and produce high levels of autoantibodies. Do not show an increase
CC       in spontaneous mutation frequency or cancer incidence. Double
CC       knockout of TREX1 and either IRF3, IFNAR1 or RAG2 fully rescues
CC       the TREX1 single knockout phenotype (PubMed:18724932).
CC       {ECO:0000269|PubMed:15254239, ECO:0000269|PubMed:18724932,
CC       ECO:0000269|PubMed:24218451}.
CC   -!- SIMILARITY: Belongs to the exonuclease superfamily. TREX family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF151106; AAD48775.2; -; mRNA.
DR   EMBL; AF319574; AAK07621.1; -; mRNA.
DR   EMBL; AK009899; BAB26571.2; -; mRNA.
DR   EMBL; AK087832; BAC40020.1; -; mRNA.
DR   EMBL; AK171916; BAE42731.1; -; mRNA.
DR   EMBL; BC011133; AAH11133.1; -; mRNA.
DR   CCDS; CCDS23544.1; -.
DR   RefSeq; NP_001012236.1; NM_001012236.1.
DR   RefSeq; NP_035767.4; NM_011637.6.
DR   UniGene; Mm.439964; -.
DR   PDB; 2IOC; X-ray; 2.10 A; A/B=1-242.
DR   PDB; 2O4G; X-ray; 2.35 A; A/B/C/D=9-245.
DR   PDB; 2O4I; X-ray; 3.50 A; A/B=9-245.
DR   PDB; 2OA8; X-ray; 2.10 A; A/B=5-234.
DR   PDB; 3B6O; X-ray; 2.10 A; A/B/C/D=9-245.
DR   PDB; 3B6P; X-ray; 2.30 A; A/B/C/D=9-245.
DR   PDB; 3MXI; X-ray; 2.55 A; A/B=1-242.
DR   PDB; 3MXJ; X-ray; 1.95 A; A/B=1-242.
DR   PDB; 3MXM; X-ray; 1.75 A; A/B=1-242.
DR   PDB; 3U3Y; X-ray; 2.28 A; A/B=1-314.
DR   PDB; 3U6F; X-ray; 2.30 A; A/B=1-314.
DR   PDB; 4YNQ; X-ray; 2.80 A; A/B/C/D=1-235.
DR   PDBsum; 2IOC; -.
DR   PDBsum; 2O4G; -.
DR   PDBsum; 2O4I; -.
DR   PDBsum; 2OA8; -.
DR   PDBsum; 3B6O; -.
DR   PDBsum; 3B6P; -.
DR   PDBsum; 3MXI; -.
DR   PDBsum; 3MXJ; -.
DR   PDBsum; 3MXM; -.
DR   PDBsum; 3U3Y; -.
DR   PDBsum; 3U6F; -.
DR   PDBsum; 4YNQ; -.
DR   ProteinModelPortal; Q91XB0; -.
DR   SMR; Q91XB0; 6-234.
DR   BioGrid; 204312; 1.
DR   STRING; 10090.ENSMUSP00000050971; -.
DR   PhosphoSite; Q91XB0; -.
DR   MaxQB; Q91XB0; -.
DR   PaxDb; Q91XB0; -.
DR   PRIDE; Q91XB0; -.
DR   Ensembl; ENSMUST00000061973; ENSMUSP00000050971; ENSMUSG00000049734.
DR   Ensembl; ENSMUST00000112053; ENSMUSP00000107684; ENSMUSG00000049734.
DR   GeneID; 22040; -.
DR   KEGG; mmu:22040; -.
DR   UCSC; uc009rrr.1; mouse.
DR   CTD; 11277; -.
DR   MGI; MGI:1328317; Trex1.
DR   eggNOG; NOG293314; -.
DR   GeneTree; ENSGT00390000012715; -.
DR   HOGENOM; HOG000118119; -.
DR   HOVERGEN; HBG079278; -.
DR   InParanoid; Q91XB0; -.
DR   KO; K10790; -.
DR   OMA; KLSLCVA; -.
DR   OrthoDB; EOG7DC26B; -.
DR   PhylomeDB; Q91XB0; -.
DR   TreeFam; TF323333; -.
DR   Reactome; REACT_300551; Regulation by TREX1.
DR   Reactome; REACT_344538; IRF3-mediated induction of type I IFN.
DR   EvolutionaryTrace; Q91XB0; -.
DR   NextBio; 301818; -.
DR   PRO; PR:Q91XB0; -.
DR   Proteomes; UP000000589; Chromosome 9.
DR   CleanEx; MM_TREX1; -.
DR   Genevisible; Q91XB0; MM.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; ISO:MGI.
DR   GO; GO:0008408; F:3'-5' exonuclease activity; ISS:UniProtKB.
DR   GO; GO:0008296; F:3'-5'-exodeoxyribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0032558; F:adenyl deoxyribonucleotide binding; IDA:MGI.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:MGI.
DR   GO; GO:0008853; F:exodeoxyribonuclease III activity; IEA:UniProtKB-EC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0032405; F:MutLalpha complex binding; ISA:MGI.
DR   GO; GO:0032407; F:MutSalpha complex binding; ISA:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0003697; F:single-stranded DNA binding; IDA:MGI.
DR   GO; GO:0035458; P:cellular response to interferon-beta; IDA:MGI.
DR   GO; GO:0000738; P:DNA catabolic process, exonucleolytic; IBA:GO_Central.
DR   GO; GO:0006259; P:DNA metabolic process; IDA:UniProtKB.
DR   Gene3D; 3.30.420.10; -; 1.
DR   InterPro; IPR006055; Exonuclease.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   SMART; SM00479; EXOIII; 1.
DR   SUPFAM; SSF53098; SSF53098; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Endoplasmic reticulum; Exonuclease; Hydrolase; Magnesium; Membrane;
KW   Metal-binding; Nuclease; Nucleus; Phosphoprotein; Reference proteome;
KW   Ubl conjugation.
FT   CHAIN         1    314       Three-prime repair exonuclease 1.
FT                                /FTId=PRO_0000109869.
FT   REGION       20     21       Substrate binding.
FT   REGION       54     63       Proline-rich region.
FT   REGION      236    314       Necessary for endoplasmic reticulum
FT                                localization.
FT   REGION      244    314       Interaction with UBQLN1. {ECO:0000250}.
FT   REGION      281    314       Necessary for cytoplasmic retention.
FT   ACT_SITE    195    195       Proton donor/acceptor.
FT                                {ECO:0000269|PubMed:17355961}.
FT   METAL        18     18       Magnesium 1.
FT   METAL        18     18       Magnesium 2.
FT   METAL        20     20       Magnesium 1.
FT   METAL       200    200       Magnesium 1.
FT   BINDING     129    129       Substrate.
FT   BINDING     200    200       Substrate.
FT   MOD_RES      78     78       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9NSU2}.
FT   MOD_RES     167    167       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9NSU2}.
FT   MOD_RES     261    261       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9NSU2}.
FT   MUTAGEN     114    114       R->H: Reduces activity. Loss of
FT                                endogenous retroelement metabolization.
FT                                {ECO:0000269|PubMed:17293595,
FT                                ECO:0000269|PubMed:18724932}.
FT   MUTAGEN     124    124       H->A: Strongly reduces activity.
FT                                {ECO:0000269|PubMed:18780819}.
FT   MUTAGEN     195    195       H->A: Loss of activity. Loss of
FT                                endogenous retroelement metabolization.
FT                                {ECO:0000269|PubMed:17355961,
FT                                ECO:0000269|PubMed:18724932,
FT                                ECO:0000269|PubMed:18780819}.
FT   MUTAGEN     200    200       D->N: Reduces activity. Loss of
FT                                endogenous retroelement metabolization.
FT                                {ECO:0000269|PubMed:18724932}.
FT   MUTAGEN     201    201       V->D: Reduces activity. Loss of
FT                                endogenous retroelement metabolization.
FT                                {ECO:0000269|PubMed:17293595,
FT                                ECO:0000269|PubMed:18724932}.
FT   CONFLICT     53     53       H -> L (in Ref. 3; AAH11133).
FT                                {ECO:0000305}.
FT   CONFLICT    269    269       R -> G (in Ref. 3; AAH11133).
FT                                {ECO:0000305}.
FT   STRAND       12     23       {ECO:0000244|PDB:3MXM}.
FT   HELIX        25     27       {ECO:0000244|PDB:3MXM}.
FT   STRAND       31     40       {ECO:0000244|PDB:3MXM}.
FT   HELIX        41     45       {ECO:0000244|PDB:3MXM}.
FT   STRAND       52     54       {ECO:0000244|PDB:3MXM}.
FT   STRAND       65     70       {ECO:0000244|PDB:3MXM}.
FT   HELIX        79     85       {ECO:0000244|PDB:3MXM}.
FT   HELIX        89     94       {ECO:0000244|PDB:3MXM}.
FT   HELIX       102    113       {ECO:0000244|PDB:3MXM}.
FT   STRAND      117    123       {ECO:0000244|PDB:3MXM}.
FT   TURN        124    129       {ECO:0000244|PDB:3MXM}.
FT   HELIX       130    139       {ECO:0000244|PDB:3MXM}.
FT   STRAND      141    143       {ECO:0000244|PDB:3MXM}.
FT   TURN        146    149       {ECO:0000244|PDB:3MXM}.
FT   STRAND      151    154       {ECO:0000244|PDB:3MXM}.
FT   HELIX       155    166       {ECO:0000244|PDB:3MXM}.
FT   HELIX       179    187       {ECO:0000244|PDB:3MXM}.
FT   STRAND      194    196       {ECO:0000244|PDB:3U3Y}.
FT   HELIX       197    208       {ECO:0000244|PDB:3MXM}.
FT   HELIX       212    222       {ECO:0000244|PDB:3MXM}.
FT   HELIX       226    228       {ECO:0000244|PDB:3MXM}.
SQ   SEQUENCE   314 AA;  33675 MW;  52C4F63A23214A7F CRC64;
     MGSQTLPHGH MQTLIFLDLE ATGLPSSRPE VTELCLLAVH RRALENTSIS QGHPPPVPRP
     PRVVDKLSLC IAPGKACSPG ASEITGLSKA ELEVQGRQRF DDNLAILLRA FLQRQPQPCC
     LVAHNGDRYD FPLLQTELAR LSTPSPLDGT FCVDSIAALK ALEQASSPSG NGSRKSYSLG
     SIYTRLYWQA PTDSHTAEGD VLTLLSICQW KPQALLQWVD EHARPFSTVK PMYGTPATTG
     TTNLRPHAAT ATTPLATANG SPSNGRSRRP KSPPPEKVPE APSQEGLLAP LSLLTLLTLA
     IATLYGLFLA SPGQ
//
